Search

Iron protein succinylate

CRx-401

has proven to be well tolerated in clinical trials. … In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and lipid profiles, and this dose

Clobutinol

Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.

Rimexolone

It is used to treat inflammation in the eye. It is marketed as Vexol.

EVT 302

EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.

TAS-106

TAS-106 is a new nucleoside antimetabolite. TAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours [A31693].

Odanacatib

Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

Anthoxanthum odoratum pollen

Anthoxanthum odoratum pollen is mainly used in allergenic testing.

Penbutolol

Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. … This binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy.

Revumenib

[L51888] In October of 20225, it was approved for myeloid leukemia patients with nucleophosmin 1 (NPM1) mutations. [L54376] … It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval.